ImmunoGenesis Highlights IMGS-203 in Two Cancer Studies
Houston, Texas, USA, November 5, 2026 ImmunoGenesis, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies, has announced...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Houston, Texas, USA, November 5, 2026 ImmunoGenesis, a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies, has announced...
Chanhassen, Minnesota, United States, October 27, 2026 Alpheus Medical has presented new clinical research findings highlighting the potential of...
Uppsala, Sweden, September 22, 2026 Beactica Therapeutics AB has announced the initiation of IND-enabling studies for BEA-17, its wholly...
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
Tel Aviv, Israel, and Oslo, Norway, September 10, 2026 BioLineRx Ltd. and Hemispherian AS have announced that two abstracts...
Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026 Telix Pharmaceuticals reported strong first-half 2026 performance, highlighting continued...
PROVIDENCE, R.I., August 18, 2026 GT Medical Technologies, Inc. announced new clinical findings suggesting that its GammaTile® targeted radiation...
Houston, Texas, August 14, 2026 Cerenome, Inc. reported continued progress across its integrated central nervous system (CNS) oncology platform,...
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
BETHESDA, Md., August 6, 2026 Northwest Biotherapeutics announced that it has entered into a non-binding Memorandum of Understanding (MOU)...
